These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1004 related articles for article (PubMed ID: 6194224)

  • 1. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo.
    Truitt RL; Shih CY; Lefever AV; Tempelis LD; Andreani M; Bortin MM
    J Immunol; 1983 Oct; 131(4):2050-8. PubMed ID: 6194224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloimmunization: induction of antileukemic reactivity without modification of anti-host reactivity in H-2-compatible mice.
    Truitt RL; Bortin MM; Rimm AA
    Transplant Proc; 1980 Mar; 12(1):143-6. PubMed ID: 6966095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic control of the induction of cytolytic T lymphocyte responses to AKR/Gross viral leukemias. I. H-2-encoded dominant gene control.
    Green WR
    J Immunol; 1984 May; 132(5):2658-64. PubMed ID: 6425409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
    Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell surface expression of cytotoxic T lymphocyte-defined, AKR/Gross leukemia virus-associated tumor antigens by normal AKR.H-2b splenic B cells.
    Green WR
    J Immunol; 1983 Dec; 131(6):3078-84. PubMed ID: 6605998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The specificity of H-2-restricted cytotoxic T lymphocytes directed to AKR/Gross leukemia virus-induced tumors. I. Isolation of a selectively resistant variant tumor subclone.
    Green WR
    Eur J Immunol; 1983 Nov; 13(11):863-70. PubMed ID: 6196206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft versus leukemia. VIII. Selective reduction in antihost reactivity without loss of antileukemic reactivity by treatment of donor mice with lipopolysaccharide.
    Truitt RL; Rose WC; Rimm AA; Bortin MM
    Exp Hematol; 1978 May; 6(5):488-98. PubMed ID: 26584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation.
    Truitt RL; Johnson BD; Hanke C; Talib S; Hearst JE
    J Immunol; 1999 Nov; 163(9):5145-56. PubMed ID: 10528221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal heterogeneity of anti-AKR/gross leukemia virus cytotoxic T lymphocytes. Evidence for two distinct antigen systems.
    Azuma H; Phillips JD; Green WR
    J Immunol; 1987 Oct; 139(7):2464-73. PubMed ID: 2821116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of F1 cytotoxic potentials by GvHR. Host- and donor-derived cytotoxic lymphocytes arise in the unirradiated F1 host spleens under the condition of GvHR-associated immunosuppression.
    Kubota E; Ishikawa H; Saito K
    J Immunol; 1983 Sep; 131(3):1142-8. PubMed ID: 6604089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of cytotoxic T cells specific for minor histocompatibility antigens by cross challenge in vitro with H-2 disparate adherent cells.
    Pilarski LM; Carayanniotis G
    J Immunol; 1985 Dec; 135(6):3686-90. PubMed ID: 2415580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic control of the induction of cytolytic T lymphocyte responses to AKR/Gross viral leukemias. II. Negative control by the Fv-1 locus in AKR mice of responder H-2b haplotype.
    Green WR
    J Immunol; 1984 May; 132(5):2665-71. PubMed ID: 6425410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The target minor H antigen for F1 cytotoxic T lymphocytes induced by Igh-congenic parental spleen cells is coded for by gene linked to H-2.
    Ishikawa H; Kubota E; Suzuki H; Saito K
    J Immunol; 1985 May; 134(5):2953-9. PubMed ID: 2580009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of F1 cytotoxic potentials by graft-vs-host reaction. Cooperative non-H-2- and H-2D region-gene control of F1 natural resistance to graft-vs-host reaction-associated immunosuppression.
    Ishikawa H; Saito K; Kubota E
    J Immunol; 1989 Mar; 142(5):1495-9. PubMed ID: 2918225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to cellular immune response in AKR leukemias.
    Schäfer A; Schmidt W
    Eur J Immunol; 1986 Jul; 16(7):753-9. PubMed ID: 2424771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.
    Fowler DH; Breglio J; Nagel G; Hirose C; Gress RE
    Biol Blood Marrow Transplant; 1996 Oct; 2(3):118-25. PubMed ID: 9199754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P; Vourka-Karussis U; Weiss L; Slavin S
    J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The specificity of H-2-restricted cytotoxic T lymphocytes directed to AKR/Gross leukemia virus-induced tumors. II. Altered gp70 display and production of noninfectious virus particles by an insusceptible variant tumor.
    Green WR; Brown MA
    Eur J Immunol; 1983 Nov; 13(11):871-7. PubMed ID: 6196207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.